Terlipressin
- Generic Name
- Terlipressin
- Brand Names
- Terlivaz
- Drug Type
- Biotech
- CAS Number
- 14636-12-5
- Unique Ingredient Identifier
- 7Z5X49W53P
- Background
Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor. It is a prodrug of lypressin, or lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. As a potent vasopressor, terlipressin has been investigated in various shock states and conditions with diminished vasomotor tone. It was also studied in hepatorenal syndrome (HRS) and variceal bleeding. The drug was first approved by the FDA in September 2022.
- Indication
Terlipressin is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. The US prescribing information states that patients with a serum creatinine > 5 mg/dL are unlikely to experience benefit from terlipressin.
- Associated Conditions
- Hepato-Renal Syndrome, Hepatorenal Syndrome Type 1, Oesophageal varices haemorrhage, Portal Hypertension
Vasoactive Drugs in Real World Practice
- Conditions
- Vasoconstrictor Choice on Acute Variceal Bleeding
- Interventions
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- Kaohsiung Veterans General Hospital.
- Target Recruit Count
- 150
- Registration Number
- NCT02757703
- Locations
- 🇨🇳
Division of Gastroenterology, Department of Internal Medicine, Kaohsiung, Taiwan
Decision Support for Intraoperative Low Blood Pressure
- Conditions
- Hypotension
- Interventions
- Procedure: Attending real-time decision supportProcedure: In-room real-time decision supportProcedure: Attending feedback emailsProcedure: In-room provider feedback emailsDevice: Anesthesia Information Management System (AIMS)Device: Perioperative Data Warehouse (PDW)Procedure: General anesthesiaDevice: Pager systemProcedure: Central neuraxial anesthesiaProcedure: Non-cardiac surgeryDrug: Ringer's lactateDrug: Hydroxyethyl starch solutionsDrug: Packed Red Blood CellsDrug: Albumin solutions
- First Posted Date
- 2016-04-04
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 22435
- Registration Number
- NCT02726620
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Effect of Terlipressin Infusion on Systemic and Hepatic Hemodynamics During Hepatobiliary Surgery
- Conditions
- Hemodynamics, Liver, Terlipressin
- Interventions
- Drug: normal saline
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 50
- Registration Number
- NCT02718599
- Locations
- 🇪🇬
Assiut University hospital, Assiut, Asyut Governorate, Egypt
To Assess Safety and Efficacy of Bolus Versus Continuous Infusion of Terlipressin in Acute Variceal Bleeding
- First Posted Date
- 2016-03-01
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 110
- Registration Number
- NCT02695862
- Locations
- 🇮🇳
Institute of liver and Biliary Sciences, New Delhi, Delhi, India
Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection.
- Conditions
- Hepatectomy, Surgical Blood Loss, Terlipressin
- Interventions
- Drug: normal saline
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2017-12-27
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 84
- Registration Number
- NCT02588716
- Locations
- 🇪🇬
Assiut University hospital, Assiut, Asyut Governorate, Egypt
To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure
- Conditions
- Acute on Chronic Liver Failure
- Interventions
- Drug: Nor adrenaline + albumin
- First Posted Date
- 2015-10-12
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 120
- Registration Number
- NCT02573727
- Locations
- 🇮🇳
Institute of liver and Biliary Sciences, New Delhi, Delhi, India
The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT02489864
- Locations
- 🇨🇳
The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
To Assess the Efficacy of Early Introduction of a Combination of Low Dose Vasopressin Analogue in Addition to Noradrenaline as a Vasopressor in Patients of Cirrhosis With Septic Shock
- Conditions
- Cirrhosis With Septic Shock
- Interventions
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 184
- Registration Number
- NCT02468063
- Locations
- 🇮🇳
Institute of Liver and Biliary Sciences, New Delhi, Delhi, India
Does Terlipressin Improve Renal Outcome After Liver Surgery
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- University of Zurich
- Registration Number
- NCT02368249
- Locations
- 🇨🇭
Department of Visceral and Transplantation Surgery of the University Hospital of Zurich, Zurich, Switzerland
Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails
- Conditions
- Esophageal and Gastric VaricesLiver CirrhosisHemorrhage
- Interventions
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 1320
- Registration Number
- NCT02311608
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.